150
Participants
Start Date
May 28, 2020
Primary Completion Date
May 30, 2025
Study Completion Date
September 30, 2025
TST001
TST001 is a humanized IgG1 monoclonal antibody.
Nivolumab Injection [Opdivo]
Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
mFOLFOX6
mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
Gemcitabine
Chemotherapy medication
Albumin-Bound Paclitaxel
Chemotherapy medication
Memorial Sloan Kettering, New York
Stony Brook Cancer Center, Stony Brook
Allegheny Hospital, Pittsburgh
Pennsylvania Cancer Specialist Research Institute, Gettysburg
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Emory University, Atlanta
Florida Cancer Specialists, Sarasota
Sarah Cannon Research Institute, Nashville
Vanderbilt University, Nashville
Gabrail Cancer Research, Canton
Medical College of Wisconsin, Milwaukee
Washington University, St Louis
University of Kansas, School of Medicine, Kansas City
NEXT Oncology, Austin
Banner MD Anderson, Gilbert
University of Arizona, Tucson
Swedish Cancer Institute, Seattle
Yale University, New Haven
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Suzhou Transcenta Therapeutics Co., Ltd.
INDUSTRY